The European CAR-T Cell Therapy Industry is Expected to Reach $1.9 Billion by 2027 –

The European CAR-T Cell Therapy Industry is Expected to Reach $1.9 Billion by 2027 –

The European CAR-T Cell Therapy Industry is Expected to Reach $1.9 Billion by 2027 –

DUBLIN–(BUSINESS WIRE)–The “Europe CAR-T Cell Therapy Market Size, Trends & Growth Opportunity, By Type, By Application, By End-user By country and Forecast till 2027.” report has been added to’s offering.

The Europe CAR-T Cell Therapy market was valued at USD 396.21 Mn in 2021 which expected to reach USD 1,904.40 Mn by 2027 at a CAGR 30.45% from 2020-2027.

Company Profiles

  • Mustang Bio Inc
  • Calgene Corporation
  • Bluebird Bio Inc.
  • Kite Pharma, Inc
  • CARsgen Therapeutics, Ltd.
  • Legend Biotech
  • Immune Therapeutics
  • Pfizer Inc
  • Bellicum Pharmaceuticals, Inc
  • Sorrento Therapeutics, Inc
  • Novartis

The CAR-T Cell Therapy market is a conceptual examination of all commercial activities related to CAR-T Cell Therapy, either directly or indirectly. As a result, a new investor can learn about CAR-T Cell Therapy firms, their important products, their basic strategy, key CAR-T Cell Therapy market trends, and more.

Market Drivers

Increasing approvals for CAR-T cell therapy products.

Increase in awareness about the new approach to treat cancer leads to increase in demand for the CAR-T cell therapy products. Thus, the key players in market are engaged in developing new products & thereby drive the growth of Europe CAR-T Cell Market.

For Instance, in June 2020, Kite Pharma, received approval to implement a variation to the Yescarta (axicabtagene ciloleucel) Marketing Authorization from the European Medicine Agency for end-to-end manufacturing. With this approval, Kite’s European manufacturing facility, designed & dedicated to the manufacture of individualized cell therapies, is now fully operational.

Market Restraints

CAR T therapies often come with unique drug development challenges. Some potential challenges associated with CAR T development is likely to hamper the growth of the Europe CAR-T Cell Therapy market. The potential challenges include limited guidance, manufacturing and distribution logistics, products safety etc.

Moreover, high cost involved in research & development for CAR-T cell therapies & lack of expertise as well as inadequate knowledge about CAR-T cell therapies are the major factors among others acting as restraints, and will further challenge the market in the forecast period.

Impact of COVID-19

Many businesses have seen their operations & financial performance suffer as a result of the COVID-19 pandemic and a slowing of global research activity. The negative impact is mostly due to the closure of academic & research institutes, as well as testing laboratories. As a result, the clinical trials conducted for the car T cell therapy has been delayed.

COVID-19 is posing a significant threat to health of vulnerable patients, like immunocompromised patients. CAR-T-cell therapy recipients are at high risk of poor COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy & CAR-T-cell therapy related side effects like B-cell depletion, hypogammaglobulinemia, and cytopenias.

Market Segmentation

By Type

  • Abecma
  • Breyanzi
  • Kymriah
  • Tecartus
  • Yescarta

By Application

  • Cancer
  • Lymphoma
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Others

By Country

  • Germany
  • France
  • UK
  • Turkey
  • Switzerland
  • Norway
  • Sweden
  • Spain
  • Denmark
  • Finland
  • Iceland
  • Poland
  • Luxembourg
  • Netherlands
  • Belgium

Key Questions Addressed by the Report

  • What are the Key Opportunities in Europe CAR-T Cell Therapy Market?
  • What will be the growth rate from 2021 to 2027?
  • Which segment/region will have highest growth?
  • What are the factors that will impact/drive the Market?
  • What is the competitive Landscape in the Industry?
  • What is the role of key players in the value chain?

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900